WO_portraits-443.jpg

Prof. Mark Kendall

CEO & Founder

(BE PhD FRSA FTSE FNAI):

 

Mark is a biomedical engineer, inventor, scientist, entrepreneur and business-builder.

Mark is the Founder and CEO of WearOptimo, advancing Microwearable sensors for precision medicine.

The companies licensing Mark’s patents/technologies have generated a combined economic value of $2 Billion.

Mark is an internationally-recognised as a leading innovator in producing technology solutions to global health problems; and a translator of commercial technologies focusing on delivery of drugs to skin and skin-based disease diagnostics.

This has culminated from more than 23 years of experience researching, developing and innovating: authoring >200 refereed publications, and being an inventor on >140 granted patents.

While at the University of Oxford, Mark was an inventor of the biolistics technology, commercialised with PowderJect (sold to Chiron Vaccines for $1 Billion in 2003), and then PowderMed, purchased by Pfizer for $400 million in 2006.

Mark was Founder, CTO and a Director of Vaxxas (2011-2015), which was the commercialisation vehicle for his Nanopatch vaccine delivery invention, featured in his TEDGlobal talk, which has >1 million views.

In recognition of Mark’s innovation and translation, he has received more than 40 awards, including: 2016 CSL Young Florey Medal, a 2015 World Economic Forum Technology Pioneer; a 2012 Rolex Laureate Award; The Australian Innovation Challenge winner (2011); the Eureka Prize for Interdisciplinary Research (2011); Younger Engineer of Britain (2004).

Mark is a Fellow of the National Academy of Inventors (FNAI), USA; the RSA (Royal Society for the encouragement of Arts, Manufactures and Commerce), UK; and The Australian Academy of Technology and Engineering (ATSE).

 

His work features in many media outlets, including: TEDGlobal, WIRED, ABC, BBC, NBC, National Geographic, New Scientist, Popular Science and Vanity Fair.

Mark is a Vice-Chancellor's Entrepreneurial Professor at ANU. At the University of Oxford (1998-2006), Mark was a University Research Lecturer and College Lecturer (Magdalen College). Then, Mark was a Professor of Biomedical Engineering at The University of Queensland (2006-2018).

Mark serves as the co-chair of the $150 million Australian Stem Cell Therapies Mission – reporting to Federal Health Minister Greg Hunt – and on the World Economic Forum Global Future Council on Biotechnology.